Oncorena AB is rated 3 out of 5 in the category pharmaceuticals. Read and write reviews about Oncorena AB. Worldwide, 270 000 persons every year are diagnosed with renal (kidney) cancer. In 1/3 of these patients the cancer has already spread and the prognosis is unfortunately very poor. Oncorena develops a product based on orellanine, with the goal of a long-term survival benefit, or even cure, for these patients.
Company size
1-10 employees
Headquarters
Lund, Skane County